AML is a renal tumor that usually exhibits a benign course. Surgical removal and embolization are the standard invasive treatment modalities. AS for AMLs is associated with a slow and consistent growth rate (0.088 cm/year), typically has minimal morbidity, and is a reasonable option in selected patients. Symptomatic presentation and size (> 3 cm) are not predictive for necessitating an invasive procedure.

No abstract

With contemporary technology and increased laparoscopic surgical experience, LRN and, in selected cases, cytoreductive LRN can be performed safely and effectively for the majority of renal tumors. Experience has resulted in a reduction in operative time and blood loss complication rates. LRN remains the approach of choice for the management of renal cortical neoplasms not amenable to nephron-sparing surgery.